DNYUZ
No Result
View All Result
DNYUZ
No Result
View All Result
DNYUZ
Home News

The tension at the heart of new healthcare tech

April 9, 2026
in News
The tension at the heart of new healthcare tech
Galleri Cancer Detection Test
Zoë Meyers for BI
  • This post originally appeared in the Business Insider Today newsletter.
  • You can sign up for Business Insider’s daily newsletter here.

A little bit of blood. A short wait. A test for more than 50 different cancers.

Grail’s Galleri test sounds too good to be true. And with cancer on the rise among young people, a simple, noninvasive test done at home sounds like a breakthrough.

Or is it?

BI’s health correspondent Hilary Brueck decided to see for herself and took the test.

What she found sits in a gray area. The test has had some success with early detection, but it’s far from perfect. Grail’s own laboratory study from 2021 said the Galleri test caught cancer just 51.5% of the time.

Hilary noted that the test doesn’t include much context or follow-up analysis. Her results were simply, “no cancer detected.”

It’s also not cheap. With a listed price of $950, it’s not something the average American can spring for. Especially when it’s essentially a coin flip whether it detects cancer at all.

Even Grail’s first CEO, Jeff Huber, sees that as a problem.

“I do feel deeply offended by the current state of things where Grail is a rich people product,” he told Hilary.

The Galleri test highlights the tension at the heart of new medical technology.

Dismissing imperfect tests feels too extreme. In a world where doctors are coming up empty on the mysterious rise of colon cancer, anything to help with early detection is a good thing.

And the more chances companies like Grail have to fine-tune the process, the closer we could get to perfection.

Investors don’t always have that kind of patience. Earlier this year, Grail announced its biggest trial yet had failed to meet its primary goal of reducing late-stage cancer diagnoses. Shortly after the news broke, its share price dropped 50%.

Optimism for new health tech, when taken to the extreme, also has limits. Just ask another blood-testing startup: Theranos.

But as long as the company is clear about a test’s limitations, as has been the case with Grail, stopping in pursuit of perfection feels like leaving a lot on the table.

Read the original article on Business Insider

The post The tension at the heart of new healthcare tech appeared first on Business Insider.

Author horrified as Trump utters ‘possibly the worst thing any American leader has said’
News

Author horrified as Trump utters ‘possibly the worst thing any American leader has said’

by Raw Story
April 9, 2026

Author Anand Giridharadas tore into President Donald Trump in a podcast discussion with The Daily Beast published Wednesday, condemning the ...

Read more
News

How Trump could still get a strategic win from the Iran war

April 9, 2026
News

The world’s 20 richest people are $90 billion wealthier after the US-Iran ceasefire sparked a big stock rally

April 9, 2026
News

Replicating the ‘Mississippi Miracle’ Won’t Be Easy

April 9, 2026
News

Pete Hegseth’s future at risk after ‘humiliating’ Trump at press conference: MS NOW host

April 9, 2026
In Germany’s East, the Far Right Could Soon Take Power. This Is Its Plan.

In Germany’s East, the Far Right Could Soon Take Power. This Is Its Plan.

April 9, 2026
The private economy is winning the space race, not NASA

The private economy is winning the space race, not NASA

April 9, 2026
Meta, Oracle and Qualcomm share details on layoffs across California

Meta, Oracle and Qualcomm share details on layoffs across California

April 9, 2026

DNYUZ © 2026

No Result
View All Result

DNYUZ © 2026